Skip to main content
logo
Regeneron Pharmaceuticals, Inc. (FRA:RGO)
Germany flag Germany · Delayed Price · Currency is EUR
641.60
-8.20 (-1.26%)
At close: Jan 23, 2026

Regeneron Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-4,4133,9544,3388,075
Depreciation & Amortization
-482.9421341.4286.2
Asset Writedown & Restructuring Costs
-12.6-195-
Loss (Gain) From Sale of Investments
--118.3266.436.8-387
Stock-Based Compensation
-982.8885725601.7
Other Operating Activities
--733.8-837.9-378.4421.6
Change in Accounts Receivable
--554-338.8707.8-1,927
Change in Inventory
--619.7-271.7-696.5-494.3
Change in Accounts Payable
-735.1598.6-138.4866.1
Change in Unearned Revenue
-227.837.932.4-120.2
Change in Other Net Operating Assets
--407.5-120.1-148.6-240.7
Operating Cash Flow
-4,4214,5945,0157,081
Operating Cash Flow Growth
--3.78%-8.39%-29.18%170.47%
Capital Expenditures
--755.9-718.6-590.1-551.9
Sale of Property, Plant & Equipment
-20.1---
Cash Acquisitions
--16.5-54.9-230.3-
Sale (Purchase) of Intangibles
--125.7-207.8-1,027-
Investment in Securities
--1,590-2,204-1,937-4,833
Investing Cash Flow
--2,468-3,185-3,785-5,385
Issuance of Common Stock
-1,4651,1461,5201,672
Repurchase of Common Stock
--3,632-2,936-2,529-2,678
Other Financing Activities
--33.4---
Financing Cash Flow
--2,201-1,790-1,009-1,006
Foreign Exchange Rate Adjustments
--0.7-0.4--
Net Cash Flow
--248.8-381.6221.3690.8
Free Cash Flow
-3,6653,8754,4256,529
Free Cash Flow Growth
--5.44%-12.42%-32.23%225.90%
Free Cash Flow Margin
-25.80%29.54%36.35%40.63%
Free Cash Flow Per Share
-31.8434.0838.9858.19
Cash Interest Paid
-52.673.153.755.8
Cash Income Tax Paid
-743870.31,5021,218
Levered Free Cash Flow
-2,6362,7632,6284,309
Unlevered Free Cash Flow
-2,6702,8082,6654,345
Change in Working Capital
--618.3-94.1-243.3-1,917
Source: S&P Global Market Intelligence. Standard template. Financial Sources.